- Home
- Publications
- Publication Search
- Publication Details
Title
Targeted Prodrug Approaches for Hormone Refractory Prostate Cancer
Authors
Keywords
-
Journal
MEDICINAL RESEARCH REVIEWS
Volume 35, Issue 3, Pages 554-585
Publisher
Wiley
Online
2014-12-22
DOI
10.1002/med.21333
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Prostate stem cell antigen antibody-conjugated multiwalled carbon nanotubes for targeted ultrasound imaging and drug delivery
- (2014) Huixia Wu et al. BIOMATERIALS
- Cancer statistics, 2014
- (2014) Rebecca Siegel et al. CA-A CANCER JOURNAL FOR CLINICIANS
- Peptide conjugates of 4-aminocyclophosphamide as prodrugs of phosphoramide mustard for selective activation by prostate-specific antigen (PSA)
- (2013) Yongying Jiang et al. BIOORGANIC & MEDICINAL CHEMISTRY
- Phase 3, randomized, placebo-controlled study of zibotentan (ZD4054) in patients with castration-resistant prostate cancer metastatic to bone
- (2012) Joel B. Nelson et al. CANCER
- 601 A First-in-human, Phase 1 Clinical Study of the Safety, Tolerability and Pharmacokinetics (PK) of G-202, a Thapsigargin-based PSMA-activated Prodrug, in Patients with Advanced Solid Tumors
- (2012) D. Mahalingam et al. EUROPEAN JOURNAL OF CANCER
- Prostate stem cell antigen-targeted nanoparticles with dual functional properties: in vivo imaging and cancer chemotherapy
- (2012) Xin Gao et al. International Journal of Nanomedicine
- Randomized, Double-Blind, Placebo-Controlled Phase III Trial Comparing Docetaxel and Prednisone With or Without Bevacizumab in Men With Metastatic Castration-Resistant Prostate Cancer: CALGB 90401
- (2012) William Kevin Kelly et al. JOURNAL OF CLINICAL ONCOLOGY
- Prospective, Randomized, Double-Blind, Vehicle Controlled, Multicenter Phase IIb Clinical Trial of the Pore Forming Protein PRX302 for Targeted Treatment of Symptomatic Benign Prostatic Hyperplasia
- (2012) Mostafa M. Elhilali et al. JOURNAL OF UROLOGY
- Engineering a Prostate-Specific Membrane Antigen-Activated Tumor Endothelial Cell Prodrug for Cancer Therapy
- (2012) S. R. Denmeade et al. Science Translational Medicine
- Prostate cancer epidemiology in the United States
- (2012) Otis W. Brawley WORLD JOURNAL OF UROLOGY
- Synthesis and structure–activity relationships of nitrobenzyl phosphoramide mustards as nitroreductase-activated prodrugs
- (2011) Longqin Hu et al. BIOORGANIC & MEDICINAL CHEMISTRY LETTERS
- Intratumoral De Novo Steroid Synthesis Activates Androgen Receptor in Castration-Resistant Prostate Cancer and Is Upregulated by Treatment with CYP17A1 Inhibitors
- (2011) C. Cai et al. CANCER RESEARCH
- Clinical potential of gene-directed enzyme prodrug therapy to improve radiation therapy in prostate cancer patients
- (2011) Alice Vajda et al. CANCER TREATMENT REVIEWS
- Molecular Chemotherapy and Chemotherapy: A New Front against Late-Stage Hormone-Refractory Prostate Cancer
- (2011) P. P. Singh et al. CLINICAL CANCER RESEARCH
- A phase II study of sorafenib in combination with bicalutamide in patients with chemotherapy-naive castration resistant prostate cancer
- (2011) Emma K. Beardsley et al. INVESTIGATIONAL NEW DRUGS
- Effects of Abiraterone Acetate on Androgen Signaling in Castrate-Resistant Prostate Cancer in Bone
- (2011) Eleni Efstathiou et al. JOURNAL OF CLINICAL ONCOLOGY
- Increased androgen receptor transcription: a cause of castration-resistant prostate cancer and a possible therapeutic target
- (2011) Masaki Shiota et al. JOURNAL OF MOLECULAR ENDOCRINOLOGY
- Denosumab versus zoledronic acid for treatment of bone metastases in men with castration-resistant prostate cancer: a randomised, double-blind study
- (2011) Karim Fizazi et al. LANCET
- Abiraterone and Increased Survival in Metastatic Prostate Cancer
- (2011) Johann S. de Bono et al. NEW ENGLAND JOURNAL OF MEDICINE
- Enzyme-mediated hydrolytic activation of prodrugs
- (2011) Yan-hui Yang et al. Acta Pharmaceutica Sinica B
- Phase 1 and 2 Studies Demonstrate the Safety and Efficacy of Intraprostatic Injection of PRX302 for the Targeted Treatment of Lower Urinary Tract Symptoms Secondary to Benign Prostatic Hyperplasia
- (2010) Samuel R. Denmeade et al. EUROPEAN UROLOGY
- Overall Survival Analysis of a Phase II Randomized Controlled Trial of a Poxviral-Based PSA-Targeted Immunotherapy in Metastatic Castration-Resistant Prostate Cancer
- (2010) Philip W. Kantoff et al. JOURNAL OF CLINICAL ONCOLOGY
- Phase II Trial of Bevacizumab, Thalidomide, Docetaxel, and Prednisone in Patients With Metastatic Castration-Resistant Prostate Cancer
- (2010) Yang-Min Ning et al. JOURNAL OF CLINICAL ONCOLOGY
- Phase II Multicenter Study of Abiraterone Acetate Plus Prednisone Therapy in Patients With Docetaxel-Treated Castration-Resistant Prostate Cancer
- (2010) Daniel C. Danila et al. JOURNAL OF CLINICAL ONCOLOGY
- Significant and Sustained Antitumor Activity in Post-Docetaxel, Castration-Resistant Prostate Cancer With the CYP17 Inhibitor Abiraterone Acetate
- (2010) Alison H.M. Reid et al. JOURNAL OF CLINICAL ONCOLOGY
- The role of HER2 in cancer therapy and targeted drug delivery
- (2010) Wanyi Tai et al. JOURNAL OF CONTROLLED RELEASE
- Antitumour activity of MDV3100 in castration-resistant prostate cancer: a phase 1–2 study
- (2010) Howard I Scher et al. LANCET
- Partners in crime: deregulation of AR activity and androgen synthesis in prostate cancer
- (2010) Karen E. Knudsen et al. TRENDS IN ENDOCRINOLOGY AND METABOLISM
- Identification of EpCAM as a Molecular Target of Prostate Cancer Stroma
- (2009) Sumana Mukherjee et al. AMERICAN JOURNAL OF PATHOLOGY
- Efficacy of carboplatin-taxane combinations in the management of castration-resistant prostate cancer: a pooled analysis of seven prospective clinical trials
- (2009) M. M. Regan et al. ANNALS OF ONCOLOGY
- Synthesis and stereochemical preference of peptide 4-aminocyclophosphamide conjugates as potential prodrugs of phosphoramide mustard for activation by prostate-specific antigen (PSA)
- (2009) Yongying Jiang et al. BIOORGANIC & MEDICINAL CHEMISTRY LETTERS
- Combined androgen blockade with bicalutamide for advanced prostate cancer
- (2009) Hideyuki Akaza et al. CANCER
- Selective Inhibition of CYP17 With Abiraterone Acetate Is Highly Active in the Treatment of Castration-Resistant Prostate Cancer
- (2009) Gerhardt Attard et al. JOURNAL OF CLINICAL ONCOLOGY
- Humanized ADEPT comprised of an engineered human purine nucleoside phosphorylase and a tumor targeting peptide for treatment of cancer
- (2009) S. Afshar et al. MOLECULAR CANCER THERAPEUTICS
- A Phase I/II Clinical Trial in Localized Prostate Cancer of an Adenovirus Expressing Nitroreductase with CB1984
- (2009) Prashant Patel et al. MOLECULAR THERAPY
- Targeting gastrin-releasing peptide receptors of prostate cancer cells for photodynamic therapy with a phthalocyanine–bombesin conjugate
- (2008) Céléna Dubuc et al. BIOORGANIC & MEDICINAL CHEMISTRY LETTERS
- Tumour endoproteases: the cutting edge of cancer drug delivery?
- (2008) J M Atkinson et al. BRITISH JOURNAL OF PHARMACOLOGY
- Docetaxel Plus Prednisone or Mitoxantrone Plus Prednisone for Advanced Prostate Cancer: Updated Survival in the TAX 327 Study
- (2008) Dominik R. Berthold et al. JOURNAL OF CLINICAL ONCOLOGY
- Phase I Clinical Trial of a Selective Inhibitor of CYP17, Abiraterone Acetate, Confirms That Castration-Resistant Prostate Cancer Commonly Remains Hormone Driven
- (2008) Gerhardt Attard et al. JOURNAL OF CLINICAL ONCOLOGY
- Crystal Structure of a Ternary Complex between Human Prostate-specific Antigen, Its Substrate Acyl Intermediate and an Activating Antibody
- (2007) Renée Ménez et al. JOURNAL OF MOLECULAR BIOLOGY
Discover Peeref hubs
Discuss science. Find collaborators. Network.
Join a conversationBecome a Peeref-certified reviewer
The Peeref Institute provides free reviewer training that teaches the core competencies of the academic peer review process.
Get Started